ALB and infection: In 2021, a randomized controlled trial study published in the New England Journal of Medicine, which included 777 hospitalized patients with decompensated cirrhosis combined with hypoproteinemia, showed no significant benefit of albumin infusion therapy compared to standard therapy in terms of the occurrence of infection, renal dysfunction, and mortality at 28 days, three months, and six months [41].